Insulin Lispro Sanofi (Insulin Lispro)

Insulin lispro mimics natural insulin by binding to insulin receptors on muscle, fat, and liver cells. This activates intracellular pathways that move glucose transporters to the cell surface, increasing glucose uptake and reducing hepatic glucose production, which rapidly lowers circulating blood sugar.

The dose of Insulin Lispro Sanofi is individualized. A qualified prescriber determines the amount based on the patient’s age, weight, carbohydrate intake, current glucose levels, and overall treatment plan. Patients should follow the dosing instructions provided by their healthcare professional.

The safety of Insulin Lispro Sanofi in pregnancy and lactation has not been fully established. It should be used only if the potential benefit justifies any possible risk to the fetus or infant. Healthcare providers will evaluate each case to decide the best course of action.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where needed), and import documentation.

Insulin lispro has a faster onset and shorter duration than regular human insulin, similar to other rapid‑acting analogs such as insulin aspart and insulin glulisine. Clinical studies show comparable efficacy in post‑prandial glucose control, with a slightly lower risk of late‑post‑prandial hypoglycaemia.

Insulin Lispro Sanofi should be stored refrigerated at 2‑8 °C (36‑46 °F). Keep the vial in its original carton, protect it from light, and avoid freezing. Once in use, the solution may be kept at room temperature (up to 25 °C) for up to 28 days, but should not be exposed to extreme heat.

The medication is administered by subcutaneous injection using a sterile syringe, pen, or insulin pump. Injection sites include the abdomen, thigh, or upper arm. Proper technique, rotating sites, and adhering to the prescriber’s dosing schedule are essential for optimal glucose control.

The most serious risks include severe hypoglycaemia, which can cause loss of consciousness or seizures, and allergic reactions ranging from local skin irritation to anaphylaxis. Prompt recognition and treatment are critical; patients should be educated on recognizing early symptoms and have a glucose source readily available.

Insulin Lispro Sanofi is contraindicated in individuals with a known hypersensitivity to insulin lispro or any of the product’s excipients. It should also be avoided in patients with severe hypoglycaemia unresponsive to treatment until the condition is resolved.